A causal link between autoantibodies and neurological symptoms in long COVID 2309692
Abstract
Abstract Introduction Acute SARS-CoV-2 infection triggers the de novo production of diverse and functional autoantibodies (AABs), even after mild illness. Previous studies have shown that autoantibodies remain persistently elevated in a subset of individuals with Long COVID (LC). However, it is still unclear whether these autoantibodies drive pathogenesis of LC Methods Using a human protein array with over 21,000 proteins and an antibody pull-down of autoantigens followed by mass spectrometry, we identified a broad range of AAB targets among individuals with LC that correlated with their symptom profiles. In order to evaluate if those autoantibodies were pathogenic, we developed a passive transfer mouse model by injecting total IgG in mice and performing a battery of behavior analysis. Results We found increased AABs against proteins in the central and peripheral nervous systems, as well as peripheral tissues, in individuals with LC displaying neurocognitive and neurological symptoms. Purified immunoglobulin G (IgG) samples from these individuals reacted with tissue sections of human locus coeruleus, thalamus, adrenal gland, thyroid, and showed cross-reactivity with mouse sciatic nerve and meninges. Autoantibody levels reactive to CNS antigens were linked to symptoms such as headaches and loss of taste and smell. Passive transfer of IgG from patients to naïve mice caused increased fatigue-like behavior and thermal hyperalgesia, aligning with patients’ reports of chronic pain. Similarly, loss of balance and coordination in the rotarod test in mice injected with IgG matched with patient-reported dizziness. Moreover, transfer of purified IgG from patients with chronic pain caused damage to small peripheral nerve fibers and increased neuronal activity in pain-related brain regions in mice. Conclusion Our findings demonstrate that transferring IgG from LC patients into mice can reproduce certain neurological symptoms, suggesting that targeting AABs might offer therapeutic benefits for this subgroup of LC. Funding Source Pew Latin American Fellowship Topic Categories Immune Mechanisms of Human Disease (HUM)
Article Details
Journal Info
The Journal of Immunology
American Association of Immunologists
Authors (26)
Keyla Sa
Yale University
Julio Silva
Yale University
Rafael Bayarri-Olmos
Yale School of Medicine
Christopher A Baker
Yale University
Zhenni Lu
Yale University
Wilson Gipson
Yale University
Daxiang Na
Bandy Chen
Li Wenxue
Yale University
Delyar Khosroabadi
Yale University
Ryan Brinda
Yale University
Robert Constable
Yale University
Britney Omene
Yale University
Patricia Colom Díaz
Yale University
Dong-il Kwon
Yale School of Medicine
Sachin Bhagchandani
Center for Nanomedicine, Department of Anesthesiology, Perioperative and Pain Medicine, Brigham and Women’s Hospital
Bornali Bhattacharjee
Yale University
Jeffrey Gehlhausen
Yale University
Jamie Wood
Icahn School of Medicine at Mount Sinai
Laura Tabacof
Icahn School of Medicine at Mount Sinai
Yansheng Liu
Leying Guan
Marc Pane
Yale University
David Putrino
Tamas Horvath
Yale University
Akiko Iwasaki
Department of Immunobiology, Yale School of Medicine